Evaluation of Serum s EGFR in Ovarian Tumors, its Comparison with Serum CA125, HE4 and Correlation with Histopathological Types

Abstract

EGFR is deregulated, in several types of cancer, by three mechanisms: (1) activating gene mutations; (2) overexpression of the EGFR transmembrane form and (3) altered ligand expression. Selective EGFR inhibitors have been suggested as first-line therapy in lung cancer patients harboring EGFR mutations, tumors of the pancreas and certain histotypes of ovarian tumors. Carbohydrate antigen 125(CA125) and Human Epididymis 4 are being used routinely for detection and follow up of ovarian cancer globally. A comparative observational study, over a 40 samples was carried out using Pre-operative and Post-operative Measurement of CA125 and HE4 by chemiluminescence and sEGFR by ELISA (Bioassay Technology Laboratory, Cat. No.E0313Hu). Results were compared between the three markers in various histological types of ovarian tumor using Statistical analysis (SPSS version 21.0). Mean pre-operative and post-operative values of sEGFR, CA125 and HE4 levels of malignant lesions were found to be higher as compared to those of benign lesions Significant decline in EGFR was seen postoperatively in benign lesions but not in CA125 and HE4, while significant decline in CA125 and HE4 was seen postoperatively in malignant lesions but not in EGFR Mean pre-operative and post-operative values of sEGFR, CA125 and HE4 levels of malignant lesions were found to be higher as compared to those of benign lesions Significant decline in EGFR was seen postoperatively in benign lesions but not in CA125 and HE4, while significant decline in CA125 and HE4 was seen postoperatively in malignant lesions but not in EGFR A combined panel of serum sEGFR, CA125, and HE4 increases the specificity and efficiency in ovarian cancer diagnosis.